NCT05442151 Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
| NCT ID | NCT05442151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tadashi Watabe |
| Condition | Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-05-09 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2022-05-09 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PET / CT examination using \[18F\] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.
Eligibility Criteria
Inclusion Criteria: Patients who meet any of the following conditions. 1. Patients who have been diagnosed with malignant tumors or suspected of having malignant tumors and have CT or FDG-PET examination. 2. Patients who have been diagnosed with malignant tumor and are scheduled to receive or have undergone anticancer treatment such as chemotherapy or radiation therapy. 3. Patients suspected of recurrence by clinical findings or diagnostic imaging such as CT or FDG-PET after treatment of malignant tumor Exclusion Criteria: 1. Pregnant women or patients who may be pregnant 2. Pediatric patients requiring sedation 3. Those who are judged to be inappropriate as subjects.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05442151 clinical trial?
This trial is open to participants of all sexes, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05442151 currently recruiting?
Yes, NCT05442151 is actively recruiting participants. Contact the research team at watabe@tracer.med.osaka-u.ac.jp for enrollment information.
Where is the NCT05442151 trial being conducted?
This trial is being conducted at Suita, Japan.
Who is sponsoring the NCT05442151 clinical trial?
NCT05442151 is sponsored by Tadashi Watabe. The trial plans to enroll 200 participants.